Taysha Gene Therapies, Inc. (TSHA)

Over the past six months, Taysha Gene Therapies reported its Q2 2025 financial results, including increased R&D expenses and a net loss, but also highlighted a strengthened balance sheet and positive clinical data for TSHA-102. The FDA granted Breakthrough Therapy Designation to TSHA-102 for Rett syndrome. Raymond James initiated coverage of Taysha Gene Therapies with a "Strong Buy" recommendation. Taysha Gene Therapies' price target was increased by 12.72% to $9.96. The company released its Q3 2025 earnings call highlights, noting increased R&D expenses and a net loss, but also emphasizing the FDA breakthrough therapy designation for TSHA-102 and its 100% response rate in Part A of the Reveal trials. Chardan Capital and Citizens maintained "Buy" and "Market Outperform" recommendations, respectively. BNK Invest committed to purchase Taysha Gene Therapies at $2.50. Taysha Gene Therapies announced progress across the TSHA-102 pivotal program, including the dosing of the first patient in the REVEAL pivotal trial in Q4 2025 and alignment with the FDA on including safety data from the ASPIRE trial in the planned Biologics License Application (BLA). The company awarded 349,000 restricted stock units (RSUs) to new employees under its 2023 Inducement Plan. The stock's 52-week high was $6.02 and its 52-week low was $1.05. As of February 6, 2026, the stock closed at $4.61. Analysts have a median target of $8.04, with a high estimate of $14.00 and a low estimate of $5.00.

For Taysha Gene Therapies, demand seasonality primarily refers to the seasonality of its stock performance rather than the demand for its products, as demand for its products is driven by the consistent medical need of patients with rare monogenic diseases. Analysis of TSHA's seasonal stock charts suggests a period of seasonal strength for the stock from March 29 to June 17, aligning with a broader seasonal strength observed in the Healthcare sector, which typically runs from April 25 to December 4. Over the past five years, this seasonal timeframe has shown positive results compared to the S&P 500 Total Return Index, with an average return of 3.19% above the benchmark.

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing and commercializing AAV-based gene therapies for severe monogenic CNS diseases, operating within the Healthcare sector and Biotechnology industry. Taysha's mission is to eradicate monogenic diseases of the central nervous system. The company's product pipeline includes gene therapy candidates like TSHA-102 for Rett syndrome (with FDA Breakthrough Therapy Designation), TSHA-120 for giant axonal neuropathy, TSHA-121 for CLN7 disease, TSHA-118 for CLN1 disease, TSHA-105 for SLC13A5 deficiency, TSHA-113 for tauopathies, TSHA-106 for Angelman syndrome, TSHA-114 for fragile X syndrome and TSHA-101 for GM2 gangliosidosis. The company also has a research, collaboration, and license agreement with The University of Texas Southwestern Medical Center.

Taysha Gene Therapies was founded in 2019 and is based in Dallas, Texas. While primarily based in the United States, TSHA-102 has received Orphan Drug designation from the European Commission and Innovative Licensing and Access Pathway designation from the Medicines and Healthcare products Regulatory Agency, indicating potential future market reach in Europe.

Taysha Gene Therapies has cultivated a positive brand reputation, particularly within the rare disease community, by focusing on a patient-centric approach. Key events that have positively affected its reputation in the past year include the FDA Breakthrough Therapy Designation for TSHA-102, positive clinical trial data with TSHA-102 demonstrating a 100% response rate in Part A of the REVEAL trials, regaining global rights to the TSHA-102 program, and a strong balance sheet with $297.3 million in cash and cash equivalents as of September 30, 2025, expected to support operations into 2028.

Taysha Gene Therapies, Inc. has significant institutional ownership, with 256 institutional owners and shareholders holding a total of 277,582,682 shares. Institutional ownership is reported to be high, ranging from 77.70% to 97.71%. Major institutional owners include Rtw Investments, Lp, Ra Capital Management, L.p., Avoro Capital Advisors LLC, Morgan Stanley, BlackRock, Inc., Fmr Llc, Goldman Sachs Group Inc, Vanguard Group Inc, Siren, L.L.C., Octagon Capital Advisors LP, Aberdeen Group plc, SG Americas Securities, LLC, Hennion & Walsh Asset Management, Inc., and Capricorn Fund Managers Ltd. Individual insiders have sold more shares than they have bought in the past three months, with sales totaling $4,518,093.00 compared to $0.00 in purchases. Only 3.78% of the stock is held by insiders.